At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of AML beyond first complete remission (CR1)
- ✓Refractory AML or AML arising from myelodysplastic syndromes
- ✓MDS with refractory anemia and excess blasts >10% in bone marrow
- ✓ALL in CR1 with high-risk features (Ph-positive, age <1 year at diagnosis, or 11q23 abnormalities)
- ✕Not pregnant or nursing; negative pregnancy test required
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies
In Brief
A Phase 2 clinical trial evaluating Busulfan and Cyclophosphamide for Chronic Myeloproliferative Disorders and 4 related conditions. Completed, enrolled 142 participants across 1 site.
Detailed Summary
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclophosphamide, mycophenolate mofetil, or tacrolimus after transplant may stop this from happening. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with tacrolimus and mycophenolate mofetil works in treating patients who are undergoing a donor bone marrow transplant for hematologic cancer.
Study Details
Timeline
Interventions
Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
Days -3, -2, +3, +4: 50 mg/kg IV daily